HealthEquity, Inc. (NASDAQ:HQY) major shareholder Berkley Capital, Llc sold 29,032 shares of the firm’s stock in a transaction dated Friday, October 6th. The shares were sold at an average price of $51.97, for a total value of $1,508,793.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Berkley Capital, Llc also recently made the following trade(s):

  • On Monday, October 9th, Berkley Capital, Llc sold 1,100 shares of HealthEquity stock. The shares were sold at an average price of $51.95, for a total value of $57,145.00.
  • On Thursday, October 5th, Berkley Capital, Llc sold 286,512 shares of HealthEquity stock. The shares were sold at an average price of $51.96, for a total value of $14,887,163.52.
  • On Friday, July 14th, Berkley Capital, Llc sold 72,791 shares of HealthEquity stock. The shares were sold at an average price of $51.41, for a total value of $3,742,185.31.

HealthEquity, Inc. (NASDAQ HQY) traded down 0.04% on Wednesday, hitting $51.32. The stock had a trading volume of 293,380 shares. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of 76.14 and a beta of 1.80. HealthEquity, Inc. has a 52-week low of $30.34 and a 52-week high of $54.95. The company’s 50 day moving average price is $46.41 and its 200 day moving average price is $46.70.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings results on Tuesday, September 5th. The company reported $0.27 EPS for the quarter, beating the Zacks’ consensus estimate of $0.14 by $0.13. HealthEquity had a net margin of 20.27% and a return on equity of 13.93%. The firm had revenue of $56.90 million during the quarter, compared to the consensus estimate of $55.66 million. During the same quarter last year, the firm earned $0.16 EPS. The firm’s revenue for the quarter was up 28.7% compared to the same quarter last year. Analysts expect that HealthEquity, Inc. will post $0.71 EPS for the current year.

WARNING: This news story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/11/healthequity-inc-hqy-major-shareholder-sells-1508793-04-in-stock.html.

Several large investors have recently made changes to their positions in HQY. Fifth Third Bancorp lifted its holdings in shares of HealthEquity by 382.8% in the 1st quarter. Fifth Third Bancorp now owns 2,414 shares of the company’s stock valued at $102,000 after acquiring an additional 1,914 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of HealthEquity in the 1st quarter valued at about $106,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of HealthEquity by 105.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,544 shares of the company’s stock valued at $127,000 after acquiring an additional 1,308 shares during the last quarter. Riverhead Capital Management LLC lifted its holdings in shares of HealthEquity by 75.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,629 shares of the company’s stock valued at $131,000 after acquiring an additional 1,129 shares during the last quarter. Finally, Exane Derivatives bought a new position in shares of HealthEquity in the 2nd quarter valued at about $132,000. 90.97% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have weighed in on HQY. Zacks Investment Research upgraded HealthEquity from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research report on Wednesday. BidaskClub downgraded HealthEquity from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Cantor Fitzgerald restated a “buy” rating and set a $56.00 price target on shares of HealthEquity in a research report on Tuesday, September 5th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $61.00 price target on shares of HealthEquity in a research report on Wednesday, September 6th. Finally, Robert W. Baird restated a “hold” rating on shares of HealthEquity in a research report on Thursday, September 21st. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $57.17.

About HealthEquity

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Insider Buying and Selling by Quarter for HealthEquity (NASDAQ:HQY)

Receive News & Stock Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related stocks with our FREE daily email newsletter.